Introduction Hu antibodies have previously been associated with longer survival of patients with small-cell lung cancer (SCLC). VGCC antibodies play a pathogenic role in the Lambert Eaton myasthenic syndrome (LEMS) which is also associated with SCLC, and these antibodies may reduce tumour growth. We tested a large cohort of sera from SCLC patients to see whether Hu and VGCC antibodies correlated with better SCLC prognosis. Method 200 patients with SCLC (age 39–79, mean 62.3 years; 129 males and 71 females) receiving similar treatment were studied. Sera from these patients were examined for Hu antibodies by an immunoprecipitation assay and by imunohistochePosters, Monday, October 28 133
